Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

13 Aug 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C.

12 Aug 2014

New disposable device may help doctors to monitor post-operative ileus

A disposal, plastic listening device that attaches to the abdomen may help doctors definitively determine which post-operative patients should be fed and which should not, an invention that may improve outcomes, decrease healthcare costs and shorten hospital stays, according to a UCLA study.

8 Aug 2014

New noninvasive method could lead to better diagnosis, treatment of gut diseases

A multi-institutional team of researchers has developed a new nanoscale agent for imaging the gastrointestinal (GI) tract. This safe, noninvasive method for assessing the function and properties of the GI tract in real time could lead to better diagnosis and treatment of gut diseases.

25 Jul 2014

Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning the role of immune-system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).

18 Jul 2014

Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).

18 Jul 2014

Independent testing organization confirms VSL#3 formulation as probiotic product

Probiotics have gained in popularity in recent years and consumers now have many to choose from. However, only 14 of 19 successfully tested through Consumer Lab's quality certification program probiotics.

9 Jul 2014

Researchers develop new "nanojuice" to help doctors better identify human gut

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots but each suffers limitations. Help is on the way.

7 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)

30 Jun 2014

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines are generally being defined as medicines which are non-mainstream medicines and are mostly given together with conventional medicines.

23 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

Squatty Potty toilet stool improves severity of constipation symptoms

When used as a treatment, the original Squatty Potty (www.squattypotty.com) toilet stool significantly improves the severity of constipation symptoms within one month of use among 84 percent of the participants of a recently released scientific study.

4 Jun 2014

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have.

21 May 2014

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will be recognized and awarded with the honorary degree, Doctor of Science Honoris Causa, from his alma mater, the University of Missouri - St. Louis, at a commencement ceremony this Saturday, May 17, 2014.

15 May 2014

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today the commercial availability of its 510(k) cleared, next-generation ENDOCAPSULE 10 System for small bowel capsule endoscopy procedures.

From Evident Corporation - Life Sciences 5 May 2014

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).

30 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

New disposable device may help doctors to monitor post-operative ileus

New noninvasive method could lead to better diagnosis, treatment of gut diseases

Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Independent testing organization confirms VSL#3 formulation as probiotic product

Researchers develop new "nanojuice" to help doctors better identify human gut

Treating ulcerative colitis and Crohn’s disease

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Squatty Potty toilet stool improves severity of constipation symptoms

Cell Science Systems launches new blood test profile for GI disorders

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Vibrating oral capsule for chronic constipation shows positive results

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Forest Laboratories enters into definitive agreement to acquire Furiex

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in